150450-42-3

Basic information

• Product Name: 4-[[3',4'-(METHYLENEDIOXY)BENZYL]AMINO]-6-METHOXYQUINAZOLINE
• Synonyms: 4-[[3',4'-(METHYLENEDIOXY)BENZYL]AMINO]-6-METHOXYQUINAZOLINE;N-(1,3-BENZODIOXOL-5-YLMETHYL)-6-METHOXY-4-QUINAZOLINAMINE
• CAS NO: 150450-42-3
• Molecular Formula: C17H15N3O3
• Molecular Weight: 309.32
• Mol File: 150450-42-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 504.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.372±0.06 g/cm3(Predicted)
• PKA: 5.53±0.50(Predicted)
• CAS DataBase Reference: 4-[[3',4'-(METHYLENEDIOXY)BENZYL]AMINO]-6-METHOXYQUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[[3',4'-(METHYLENEDIOXY)BENZYL]AMINO]-6-METHOXYQUINAZOLINE(150450-42-3)
• EPA Substance Registry System: 4-[[3',4'-(METHYLENEDIOXY)BENZYL]AMINO]-6-METHOXYQUINAZOLINE(150450-42-3)

Safety Data

• Hazardous Substances Data: 150450-42-3(Hazardous Substances Data)

Upstream product

• 2620-50-0 1,3-benzodioxol-5-ylmethyl amine 
• 50424-28-7 4-chloro-6-methoxyquinazoline 

Relevant articles and documents

Method of treating a patient having a precancerous lesions with amide quinazoline derivatives

Derivatives of quinazoline are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit the growth of neoplastic cells.

Cyclic GMP Phosphodiesterase Inhibitors. 2. Requirement of 6-Substitution of Quinazoline Derivatives for Potent and Selective Inhibitory Activity

We synthesized various 4-amino>quinazolines substituted at the 5- to 8-positions and evaluated their inhibitory activities toward cyclic GMP phosphodiesterase (cGMP-PDE) from porcine aorta.Monosubstitution at the 6-position was essential for the inhibitory activity, and the preferred substituents were compact and hydrophobic: methoxy (3b, IC50 = 0.23 μM), methyl (3c, 0.10 μM), chloro (3d, 0.019 μM), thiomethyl (3f, 0.031 μM), and cyano (3p, 0.090 μM) groups.Compounds 3b-d, f, p lacked inhibitory activity toward other PDE isozymes (all IC50 values > 100 μM), and their relaxing activities in porcine coronary arteries were well correlated with the inhibitory activities toward cGMP-PDE (r = 0.88, p 0.05).One of these compounds, 3b, elevated the intracellular cGMP level in isolated porcine coronary arteries without causing any change in the cAMP level.We consider that this series of compounds dilates coronary arteries via potent and specific inhibition of cGMP-PDE.